Kolkata, West Bengal -- (SBWIRE) -- 09/16/2013 -- Specialpennystockalert.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on Inovio Pharmaceuticals Inc (NYSEMKT:INO), Cell Therapeutics Inc (NASDAQ:CTIC), The Wendy's Company (NASDAQ:WEN).
Inovio Pharmaceuticals Inc (NYSEMKT:INO) shares increased 5.38% to $2.35. Roche (six:RO)(six:ROG)(otcqx:RHHBY) and Inovio Pharmaceuticals, Inc. on Sept. 10 announced that they have entered into an exclusive worldwide license agreement to research, develop and commercialize Inovio's highly-optimized, multi-antigen DNA immunotherapies targeting prostate cancer and hepatitis B. The licensed compounds are currently in preclinical development and have generated robust T-cell responses in animal models.
Additionally, the company announced that Dr. J. Joseph Kim, President and CEO, presented a corporate overview of the company at the Rodman & Renshaw Global Investment Conference and the Stifel Nicolaus Weisel Healthcare Conference on Tuesday, September 10, 2013 11:15 AM ET and Thursday, September 12, 2013 10:55 AM ET respectively.
Should Investors Buy INO After Yesterday’s Jump? Find Out Here
Cell Therapeutics Inc (NASDAQ:CTIC) shares gained 20.18% to $1.31. The company on Sept. 13 announced that it has agreed to sell 15,000 shares of its Series 18 Preferred Stock directly to Quogue Capital LLC and an affiliate of Perceptive Advisors LLC in a registered direct offering conducted without an underwriter or placement agent for gross proceeds of approximately $15 million (the "Offering"). The net proceeds from the Offering, after deducting estimated offering expenses, will be approximately $14.8 million.
How Should Investors Trade CTIC After The Recent Volatility? Get Free Trend Analysis Here
The Wendy's Company (NASDAQ:WEN) shares dropped 0.46% to $8.58. WEN’s stock was upgraded by investment analysts at Argus from a “hold” rating to a “buy” rating in a note issued to investors on Sept. 12. The firm currently has a $10.00 price target on the stock. Separately, analysts at Zacks reiterated an “outperform” rating on shares of WEN in a research note to investors on August 16. They now have a $9.25 price target on the stock.
Is WEN A Good Buy After The Recent Price Movement? Find Out Here
Specialpennystockalert.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. Specialpennystockalert.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed "informational edge" which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at Specialpennystockalert.com.
The assembled information disseminated by Specialpennystockalert.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Specialpennystockalert.com does expect that investors will buy and sell securities based on information assembled and presented in phd-trading.com. PLEASE always do your own due diligence, and consult your financial advisor.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)